CORRECTED May 2, 2013 at 12:30 p.m. This article originally mis-stated the nature of an expected insurance settlement and of Wright’s adjusted earnings-per-share forecast.
2013
NuVasive’s Q1 sales rise, profits surge as it settles beef with Medtronic
Investors failed to reward NuVasive Inc. (NSDQ:NUVA) for reporting mid-single-digit sales growth and double-digit profit growth during the 1st quarter, sending shares down slightly today on Wall Street after the medical device company lowered its full-year earnings forecast.
Teleflex slides despite Street-beating Q1 numbers, reaffirmed guidance
HeartWare surges after Q1 results skewer expectations
Shares of HeartWare International (NSDQ:HTWR) are up by more than 10% today after the heart pump maker skewered expectations with its 1st-quarter results, reporting nearly 87% top-line growth and paring losses by more than ⅓.
M&A: Bayer buys Conceptus for $1.1 billion
Sluggish results continue to roll in across the med-tech sector
Covidien’s Q2 profits slide 12%
Varian slides amid uncertainty in U.S. and E.U. oncology markets
Varian Medical Systems (NYSE:VAR) was none too pleased with the market for its oncology systems, calling its Q2 revenues for that division "disappointing, particularly in the U.S."
Boston Scientific ticks up on Q1 earnings beat despite sales slide, lowered forecast
Boston Scientific (NYSE:BSX) saw share prices gain slightly this morning after beating Wall Street’s earnings expectations by a healthy margin, despite a $423 million write-down on the value of its cardiac rhythm management business stemming from a reorganization of the Natick, Mass.-based medical device company.
Zimmer hits the mark, but spine sales continue to slide
Recall, DoJ probe push Stryker’s Q1 profits down 13%
Stryker (NYSE:SYK) said the recall of some of its hip implant components and a U.S. Justice Dept. probe into its OtisKnee device helped push 1st-quarter profits down 13%, but still managed to beat Wall Street analysts’ expectations.
Kalamazoo, Mich.-based Stryker posted profits of $304 million, or 79¢ per share, on sales of $2.19 billion during the quarter, amounting to 1.3% sales growth.